Dong-Wen Lv (Dongwen Lv)

Scopus Author ID ResearcherID Scopus Author ID Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 22

Top Venues

The Journal of experimental medicine

Nature communications

Blood

PLoS pathogens

University of Florida

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Florida May 31 2019

United States

Research assistant professor :: College of Pharmacy

University of Florida Jun 01 2018 - May 30 2019

United States

Postdoc associate :: College of Pharmacy

University of Arkansas for Medical Sciences Oct 01 2017 - May 24 2018

United States

Postdoc :: College of Pharmacy

Publications

Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Amin Sobh, Elena Encinas, Alisha M Patel, Greeshma Surapaneni, Emilie Bonilla, Charlotte Kaestner, Janai Poullard, Monica Clerio, Karthik Vasan, Tzipporah Freeman, Dong-Wen Lv, Daphné Dupéré-Richer, Alberto Riva, Benjamin G Barwick, Daohong Zhou, Lawrence H Boise, Constantine S Mitsiades, Baek Kim, Richard L Bennett, Navdeep S Chandel, Jonathan D Licht
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome. Blood 144 (3) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Amin Sobh, Elena Encinas, Alisha M Patel, Greeshma Surapaneni, Emilie Bonilla, Charlotte Kaestner, Janai Poullard, Monica Clerio, Karthik Vasan, Tzipporah Freeman, Dong-Wen Lv, Daphné Dupéré-Richer, Alberto Riva, Benjamin G Barwick, Daohong Zhou, Lawrence H Boise, Constantine S Mitsiades, Baek Kim, Richard L Bennett, Navdeep S Chandel, Jonathan D Licht
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome. Blood 144 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Amin Sobh, Elena Encinas, Alisha M Patel, Greeshma Surapaneni, Emilie Bonilla, Charlotte Leonie Kaestner, Janai Poullard, Monica Clerio, Karthik Vasan, Tzipporah Freeman, Dong-Wen Lv, Daphné Dupéré-Richer, Alberto Riva, Benjamin G Barwick, Daohong Zhou, Lawrence H Boise, Constantine S Mitsiades, Baek Kim, Richard L Bennett, Navdeep S Chandel, Jonathan D Licht
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome. Blood (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Digant Nayak, Dong-Wen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, Guangrong Zheng, Daohong Zhou, Shaun K Olsen
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nature communications 15 (1) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily K Moser, Keiran S M Smalley, Dong-Wen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of experimental medicine 221 (3) (2024)
Dong-Wen Lv, Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang, Wanyi Hu, Jing Pei, Qi Zhang, Shuo Zhou, Sajid Khan, Xuan Zhang, Nan Hua, Qingping Yang, Sebastian Arango, Weizhou Zhang, Digant Nayak, Shaun K Olsen, Susan T Weintraub, Robert Hromas, Marina Y Konopleva, Yaxia Yuan, Guangrong Zheng, Daohong Zhou
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature communications 12 (1) (2021)
Yong-Han He, Wen Li, Dong-Wen Lv, Xin Zhang, Xuan Zhang, Yuma T Ortiz, Vivekananda Budamagunta, Pierre-Yves Desprez, Guangrong Zheng, Daohong Zhou
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging cell 19 (3) (2020)
Yong-Han He, Xuan Zhang, Jianhui Chang, Ha-Neui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dong-Wen Lv, Lin Song, Wen Li, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Yuma T Ortiz, Vivekananda Budamagunta, Jennifer H Elisseeff, Judith Campisi, Maria Almeida, Guangrong Zheng, Daohong Zhou
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nature communications 11 (1) (2020)
Sajid Khan, Xuan Zhang, Dong-Wen Lv, Qi Zhang, Yonghan He, Peiyi Zhang, Xingui Liu, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Jing Pei, Weizhou Zhang, Abhisheak Sharma, Christopher R McCurdy, Vinitha M Kuruvilla, Natalia Baran, Adolfo A Ferrando, Yong-Mi Kim, Anna Rogojina, Peter J Houghton, Guangcun Huang, Robert Hromas, Marina Konopleva, Guangrong Zheng, Daohong Zhou
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature medicine 25 (12) (2019)
Dong-Wen Lv, Kun Zhang, Renfeng Li
Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction. PLoS pathogens 14 (1) (2018)

Dong-Wen Lv.css-eqlu8i{font-size:small;padding-left:4px;} (Dongwen Lv)

Publication Activity (10 Years)

Top Topics

Top Venues

Dong-Wen Lv (Dongwen Lv)